The Role of HRD Testing in Cancer

This webinar aims to review and discuss different methods for HRD testing, the clinical aspects of HRD as a predictive/prognostic biomarker in ovarian cancer and to understand the role of HRD testing in other tumour types.

Chair

Rowan Miller

Speakers

James Brenton, Violeta Serra, Wassim Abida

Programme

• Welcome and Introduction - Where are we now with HRD as a Predictive/Prognostic Biomarker in Ovarian Cancer, Dr. Rowan Miller, University College London, St Bartholomew's Hospitals, London, UK
• Evaluating HRD Status Using Gene Signatures and Scar Assays, Prof. James Brenton, Cancer Research UK Cambridge Institute, Cambridge Research Institute, Cambridge, UK
• Functional HRD Assays – Ready for Prime Time?, Dr. Violeta Serra, Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
• HRD Testing Beyond Ovarian Cancer - The Role in GU Cancers and Others, Dr. Wassim Abida, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, US
• Q&A
• Closing Remarks, Dr. Rowan Miller, University College London, St Bartholomew's Hospitals, London, UK

Learning Objectives

• To understand the role of HRD testing in cancer
• To understand different methods for HRD testing
• To understand the clinical aspects of HRD as a predictive/prognostic biomarker in ovarian cancer
• To understand the role of HRD testing beyond ovarian cancer